13 Biotech Stocks with Huge Upside Potential

9. Insmed Incorporated (NASDAQ:INSM)

Analysts’ Upside Potential as of June 9: 35.72%

Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment’s impending Phase 2 data for pulmonary arterial hypertension.

Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment.

On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107.

Shi points out that TPIP’s once-daily dosage is a significant benefit over Tyvaso’s four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD).

Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)’s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases.